Compare Five Below Inc (FIVE) vs Johnson & Johnson (JNJ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Five Below Inc vs Johnson & Johnson — how do they compare? Five Below Inc trades at $215.28 (market cap $11.55B), while Johnson & Johnson trades at $261.2 (market cap $618.09B). The key difference: Johnson & Johnson is far larger — about 53.5× Five Below Inc's market cap, and Johnson & Johnson pays a 2.09% dividend while Five Below Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Five Below Inc for 46 Days and Johnson & Johnson for 129 Days on average.
| FIVE | JNJ | |
|---|---|---|
Market Cap | $11.55B | $618.09B |
Volume | 1,120,554 | 6,050,983 |
Sector | Consumer Cyclical | Health |
52-Week High | $262.72 | $278.43 |
52-Week Low | $138.49 | $186.00 |
Typical Hold Time | 46 Days | 129 Days |
Enterprise Value | $12.40B | $646.37B |
Dividend Yield | — | 2.09% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Five Below (FIVE) trades at $213.30, up 4.44% today, with strong earnings beats in recent quarters and a bullish analyst consensus of 60% buy ratings. The stock shows bearish technical signals but maintains solid fundamentals with 40.26% gross margins and 28.25% ROE. Recent news highlights growth initiatives including a $600 million buyback and board appointments.
Outlook remains positive with revenue projected to grow to $5.3 billion in 2026 and net income margin improving to 11.65%. Risks include premium valuation (P/E 18.81) and execution pressure amid economic headwinds. The consensus price target of $298.44 suggests 40% upside potential from current levels.
Johnson & Johnson (JNJ) trades at $259.62, up 0.45% with a bearish technical signal despite recent earnings beats. The stock shows strong fundamentals with 21.48% net margin and 25.74% ROE, though valuation ratios appear elevated with P/E at 29.75. Recent news highlights growth in the Innovative Medicine segment and positive analyst coverage with 52.5% buy ratings.
JNJ offers stable dividend income and pharmaceutical innovation upside, but faces patent cliff risks and increasing debt-to-asset ratio (24.06% in 2025). Analyst consensus target of $286.53 suggests 10% upside potential, though technical resistance at $260 may limit near-term gains.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Five Below Inc
Five Below is a value-oriented retailer that operated 1,190 stores in the United States as of the end of fiscal 2021. Catering to teen and preteen consumers, stores feature a wide variety of merchandise, the vast majority of which is priced below $6. The assortment focuses on discretionary items in several categories, particularly leisure (such as sporting goods, toys, and electronics
Read more on FIVE →About Johnson & Johnson
Johnson & Johnson manufactures health care products and provides related services for the consumer, pharmaceutical, and medical devices and diagnostics markets. The Company sells products such as skin and hair care products, acetaminophen products, pharmaceuticals, diagnostic equipment, and surgical equipment in countries located around the world.
Read more on JNJ →
